[{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"d6f097ba-9519-4376-8dfc-112499960700","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840409","created_at":"2021-01-18T13:56:34.086Z","updated_at":"2024-07-02T16:35:21.598Z","phase":"Phase 2","brief_title":"Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","source_id_and_acronym":"NCT02840409","lead_sponsor":"The Hospital for Sick Children","biomarkers":" BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1","pipe":" | ","alterations":" BRAF mutation • FGFR1 fusion","tags":["BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • FGFR1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-01-31"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"bbd1a478-a3ea-4485-aa56-e8b3f93758ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975701","created_at":"2021-01-18T08:59:44.203Z","updated_at":"2024-07-02T16:36:52.939Z","phase":"Phase 2","brief_title":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","source_id_and_acronym":"NCT01975701","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1","pipe":" | ","alterations":" FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation","tags":["FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 10/03/2018","primary_completion_date":" 10/03/2018","study_txt":" Completion: 10/03/2018","study_completion_date":" 10/03/2018","last_update_posted":"2019-12-04"},{"id":"819807a7-627e-40e5-a967-fc5eec1c4f69","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT02824133","created_at":"2021-01-18T13:50:52.751Z","updated_at":"2024-07-02T16:36:59.263Z","phase":"Phase 1/2","brief_title":"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion\"","source_id_and_acronym":"NCT02824133 - TARGET","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FGFR • TACC3 • TACC1","pipe":" | ","alterations":" FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion","tags":["FGFR • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-05-29"}]